AAAAAA
Results:
1-11
|
Results: 11
Authors:
Maliepaard, M
van Gastelen, MA
Tohgo, A
Hausheer, FH
van Waardenburg, RCAM
de Jong, LA
Pluim, D
Beijnen, JH
Schellens, JHM
Citation: M. Maliepaard et al., Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918, CLIN CANC R, 7(4), 2001, pp. 935-941
Authors:
Walkey, DJ
Smy, TJ
MacElwee, TW
Maliepaard, M
Citation: Dj. Walkey et al., Linear models for temperature and power dependence of thermal resistance in Si, InP and GaAs substrate devices, P IEEE SEM, 2001, pp. 228-232
Authors:
Schellens, JHM
Planting, AST
Ma, J
Maliepaard, M
de Vos, A
Dennert, MD
Verweij, J
Citation: Jhm. Schellens et al., Adaptive intrapatient dose escalation of cisplatin in patients with advanced head and neck cancer, ANTI-CANC D, 12(8), 2001, pp. 667-675
Authors:
Maliepaard, M
Scheffer, GL
Faneyte, IF
van Gastelen, MA
Pijnenborg, ACLM
Schinkel, AH
van de Vijver, MJ
Scheper, RJ
Schellens, JHM
Citation: M. Maliepaard et al., Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues, CANCER RES, 61(8), 2001, pp. 3458-3464
Authors:
Erlichman, C
Boerner, SA
Hallgren, CG
Spieker, R
Wang, XY
James, CD
Scheffer, GL
Maliepaard, M
Ross, DD
Bible, KC
Kaufmann, SH
Citation: C. Erlichman et al., The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistanceprotein-mediated drug efflux, CANCER RES, 61(2), 2001, pp. 739-748
Authors:
Sargent, JM
Williamson, CJ
Maliepaard, M
Elgie, AW
Scheper, RJ
Taylor, CG
Citation: Jm. Sargent et al., Breast cancer resistance protein expression and resistance to daunorubicinin blast cells from patients with acute myeloid leukaemia, BR J HAEM, 115(2), 2001, pp. 257-262
Authors:
Jonker, JW
Smit, JW
Brinkhuis, RF
Maliepaard, M
Beijnen, JH
Schellens, JHM
Schinkel, AH
Citation: Jw. Jonker et al., Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan, J NAT CANC, 92(20), 2000, pp. 1651-1656
Authors:
Scheffer, GL
Maliepaard, M
Pijnenborg, ACLM
van Gastelen, MA
de Jong, MC
Schroeijers, AB
van der Kolk, DM
Allen, JD
Ross, DD
van der Valk, P
Dalton, WS
Schellens, JHM
Scheper, RJ
Citation: Gl. Scheffer et al., Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines, CANCER RES, 60(10), 2000, pp. 2589-2593
Authors:
de Graaff, M
Maliepaard, M
Pluim, D
Floot, BJG
Slaper-Cortenbach, ICM
Schellens, JHM
Citation: M. De Graaff et al., In vitro antagonistic cytotoxic interactions between platinum drugs and taxanes on bone marrow progenitor cell CFU-GM, ANTI-CANC D, 10(2), 1999, pp. 213-218
Authors:
Maliepaard, M
van Gastelen, MA
de Jong, LA
Pluim, D
van Waardenburg, RCAM
Ruevekamp-Helmers, MC
Floot, BGJ
Schellens, JHM
Citation: M. Maliepaard et al., Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line, CANCER RES, 59(18), 1999, pp. 4559-4563
Authors:
Pluim, D
Maliepaard, M
van Waardenburg, RCAM
Beijnen, JH
Schellens, JHM
Citation: D. Pluim et al., P-32-postlabeling assay for the quantification of the major platinum-DNA adducts, ANALYT BIOC, 275(1), 1999, pp. 30-38
Risultati:
1-11
|